SCHEMBL2812418

SCHEMBL2812418

O=C1COc2cc(Br)ccc2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP1A2 P05177 2/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
PKM P14618 1/20 0.41
NPR1 P16066 1/20 0.41
TSHR P16473 1/20 0.41
AHR P35869 4/20 0.41
CMA1 P23946 1/20 0.41
METAP1 P53582 1/20 0.40
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
APP P05067 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TDP2 O95551 1/20 0.39
PARP1 P09874 1/20 0.35
PARP10 Q53GL7 1/20 0.35
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1758974 0.85 APP (0.42) BLMTDP1CYP1A2TP53CYP3A4
SCHEMBL12988342 0.79 BLM (0.57) BLMTDP1CYP1A2TP53CYP3A4
SCHEMBL28020004 0.78 NR3C2 (0.39) CYP1A2MAPTL3MBTL1PARP1PARP10
SCHEMBL13156965 0.78 MAPT (0.44) CYP1A2LMNAMAPT
SCHEMBL12431219 0.78 AHR (0.41) CYP1A2AHRCMA1METAP1MAPT
SCHEMBL18983714 0.78 DRD2 (0.46) CYP3A4MAPTMAOAMAOB
SCHEMBL10964903 0.75 APP (0.50) BLMTDP1CYP1A2TP53CYP3A4
SCHEMBL18998227 0.75 CYP1A2 (0.33) CYP1A2
SCHEMBL3962887 0.74 CYP1A2 (0.54) CYP1A2PKMTSHRLMNAMAPT
SCHEMBL30450885 0.74 CYP1A2 (0.54) CYP1A2PKMTSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115297930-B Antimicrobial compounds and methods 库扎环球有限责任公司 2025-02-14 CN disclosed
EP-4058146-B1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL LLC (US) 2024-10-23 EP disclosed
US-20230278987-A1 Antimicrobial Compounds and Methods CURZA GLOBAL, LLC. 2023-09-07 US disclosed
US-20230278987-A1 Antimicrobial Compounds and Methods CURZA GLOBAL, LLC. 2023-09-07 US disclosed
CN-115297930-A Antimicrobial compounds and methods 库扎环球有限责任公司 2022-11-04 CN disclosed
EP-4058146-A1 ANTIMICROBIAL COMPOUNDS AND METHODS Curza Global LLC (US) 2022-09-21 EP disclosed
WO-2021097061-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2021-05-20 WO disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 US disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 US disclosed
US-9115151-B2 Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof ABBVIE INC. (US) 2015-08-25 US disclosed
CN-104844549-A Preparation method of 7 - bromine pyran derivatives Hunan huateng pharmaceutical co ltd 2015-08-19 CN disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 US disclosed
EP-2188273-B1 SUBSTITUTED TETRA HYDRO NAPHTHALINES, METHOD FOR THEIR MANUFACTURE AND THEIR USE AS DRUGS SANOFI SA (FR) 2014-10-22 EP disclosed
US-20140206663-A1 TRIAZINONE COMPOUNDS WUXI APPTECH (SHANGHAI) CO., LTD. (CN) 2014-07-24 US disclosed
US-20140088077-A1 NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS SANOFI (FR) 2014-03-27 US disclosed
US-8609731-B2 Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments SANOFI (FR) 2013-12-17 US disclosed
US-20100249097-A1 NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS SANOFI-AVENTIS (FR) 2010-09-30 US disclosed
EP-2188273-A2 NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS Sanofi-Aventis (FR) 2010-05-26 EP disclosed
WO-2009021740-A2 SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS SANOFIS-AVENTIS (FR) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278987-A1 Antimicrobial Compounds and Methods CLPP, RPN2, MPO BLM 3119/4885TDP1 3800/4885CYP1A2 4279/4885
US-20140088077-A1 NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS DHPS, CYP11B2, CYP11B1 BLM 4487/4885TDP1 2064/4885CYP1A2 39/4885
US-20140206663-A1 TRIAZINONE COMPOUNDS THPO, IL5, CYP11B2 BLM 3409/4885TDP1 4157/4885CYP1A2 34/4885
US-20100249097-A1 NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS DHPS, CYP11B2, CYP11B1 BLM 4487/4885TDP1 2064/4885CYP1A2 39/4885
US-20150038488-A1 SYK INHIBITORS SYK, BTK, LYN BLM 858/4885TDP1 402/4885CYP1A2 3466/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN BLM 848/4885TDP1 428/4885CYP1A2 3603/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN BLM 848/4885TDP1 428/4885CYP1A2 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.